{Reference Type}: Journal Article
{Title}: RAAS in diabetic retinopathy: mechanisms and therapies.
{Author}: Li X;Fu YH;Tong XW;Zhang YT;Shan YY;Xu YX;Pu SD;Gao XY;
{Journal}: Arch Endocrinol Metab
{Volume}: 68
{Issue}: 0
{Year}: 2024 Apr 19
{Factor}: 2.032
{DOI}: 10.20945/2359-4292-2023-0292
{Abstract}: Diabetic retinopathy (DR) is a complication of diabetes with a complex pathophysiology and multiple factors involved. Recently, it has been found that the upregulation of the renin-angiotensin-aldosterone system (RAAS) leads to overexpression of angiotensin II (Ang II), which induces oxidative stress, inflammation, and angiogenesis in the retina. Therefore, RAAS may be a promising therapeutic target in DR. Notably, RAAS inhibitors are often used in the treatment of hypertension. Still, the potential role and mechanism of DR must be further studied. In this review, we discuss and summarize the pathology and potential therapeutic goals of RAAS in DR.